SRC and cancer: Since activating Src mutations are rare in human cancers, aberrant Src activity is presumably dependent on increased Src expression or stimulation by growth factors and interleukins abundant in the tumor microenvironment, including EGF, IGF, IL-6, IL-8 (37).